Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New obesity drug eloralintide tested in chinese volunteers

NCT ID NCT06916091

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tested a single dose of the investigational drug eloralintide in 30 Chinese adults who are overweight or have obesity. The main goal was to check safety and side effects, and to measure how the drug moves through the body. Participants were randomly assigned to receive either the drug or a placebo injection under the skin.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

30 people

The number who actually took part.

Started

Apr 2025

Finished

Sep 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

21 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Chinese participants. To qualify as Chinese, all 4 of the participant's biological grandparents must be of exclusive Chinese descent and born in China * Have had a stable body weight for 3 months prior to screening. Participants with body weight change of less than 5% will be allowed * Have not modified diet or adopted any nutritional lifestyle modification for 3 months before randomization * Have clinical laboratory test results within a normal range for the population or investigative site at screening and lead-in, or results with acceptable deviations that are judged to be not clinically significant by the investigator * Have a body mass index (BMI) within the range 27 to 40 kilogram per square meter (kg/m²) Exclusion Criteria: * Are pregnant, or intend to become pregnant or to breastfeed during the study * Have known allergies to related compounds of eloralintide * Have any of the following abnormal blood pressure (BP) and/or pulse rate at screening, constituting a risk when taking the investigational product with minor deviations judged to be acceptable by the investigator: * Supine BP \> 160/90 millimeter mercury (mmHg) * Supine pulse rate \< 50 or \> 100 beats per minute (bpm) * Orthostatic hypotension * Have significant previous or current history of comorbidities capable of significantly altering the absorption, metabolism, or elimination of drugs * Regularly use known drugs of abuse and/or show positive findings on drug screening that are not consistent with the medical history or concomitant medication history * Have donated blood of more than 450 mL within the previous 3 months of study screening, or intend to donate blood during the course of the study * Have a history of chronic medical conditions involving the heart, liver, or kidneys * Have a medical history or current evidence of clinically significant cardiac condition

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obesity are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Lilly Centre for Clinical Pharmacology

    Singapore, 138623, Singapore

More trials for these conditions

Other studies related to the condition(s) this trial covers.